Denitza Zheleva*and Razvigor Darlenski
Department of Dermatology and Venereology, Tokuda Hospital Sofia, Bulgaria
Received: 10 February, 2017; Accepted: 23 February, 2017; Published: 24 February, 2017
Denitza Zheleva, Department of Dermatology and Venereology, Tokuda Hospital Sofia, 51B, Nikola Vaptzarov blvd, 1407 Sofia, Bulgaria, Tel: 00359 895 788551; E-mail:
Zheleva D, Darlenski R (2017) Atopic Eczema - From Epidemiology to Therapeutic Approach. Glob J Allergy 3(1): 004-010. DOI: 10.17352/2455-8141.000016
© 2017 Zheleva D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Atopic dermatitis is one of the epidemically expanding non-infectious diseases in the 21 century. It poses immense challenges to both patients and physicians. With a steady growth in its incidence and prevalence, the disease carries a heavy social and economical burden. Herein we discuss the therapeutic algorithm for atopic dermatitis in accordance with the disease severity. We emphasize on the personalized approach in selecting the proper treatment method and regimen for each patient.
Atopic dermatitis (AD, syn. ‘atopic eczema’) is the commonest inflammatory skin disorder in children and represents a serious problem for the providers of health care all over the world [1-4] with an impressive effect on patients’ quality of life [1,5-9]. In 40–60% of paediatric patients with AD persist having symptoms later on in life [10,11]. Although AD often starts in early infancy, there are adult onset forms which start in adolescence or adulthood . Most of the patients with AD can control their skin disease with topical therapy and emollient skin care. There is a considerable group of patients with severe AD who do not respond to the prescribed treatment with moisturizers, topical corticosteroids (TCS), and/or topical calcineurin inhibitors (TCI) or experience immediate flare-ups after tapering topical anti-inflammatory therapy.
The European Academy of Allergology and Clinical Immunology (EAACI)  suggested definition of the term atopy – ‘a personal or familial tendency to produce IgE antibodies in response to low doses of allergens, usually proteins, and to develop typical symptoms of asthma, rhinoconjunctivitis or eczema/dermatitis’. As an alternative term the authors also suggested ‘atopic eczema/dermatitis syndrome’ . In 2003, the Nomenclature Review Committee of the World Allergy Organization (WAO) updated the EAACI 2001 position statement  and suggested that the term ‘eczema’ should replace the provisional term ‘atopic eczema/dermatitis syndrome’. The update further suggested that ‘eczema’ could be subclassified as ‘atopic eczema’ and ‘nonatopic eczema’ according to the presence or absence of IgE antibodies.
The pathophysiology and clinical phenotype of AD are very heterogeneous and change from patient to patient as well as within the history of a given patient. The disease has great impact over patients’ quality of life and beyond, a socio-economic burden. Moderate to severe AD causes over two billion euro in lost productivity in the European Union (EU) every year [14,15]. Lapidus et al., estimated that the annual amount spent on ambulatory care, emergency department care, inpatient care, and outpatient prescriptions for American children with AD is US$364 . The cost of medical services and prescription drugs was estimated to be between US$0.9 and US$3.8 billion in the United States between 1997 and 1998.
For the last 30 years there is a dramatic increase in the prevalence of AD. It has increased from 9% to 12% for 10 year period between 1960 and 1970 , and nowadays the prevalence is approximately between 15-20% [10,18]. In developed countries it is currently estimated between 10-20% for children and 1-3% for adults. Last studies reveal that the prevalence range in various borders according to the goegraphic regions and the environmental factors. It varies for different countries: less than 1- 2% in Iran and Albania, approximately 11 % for the United States, up to 16-17% in Japan and Nigeria. The Australasia and Northern Europe shows higher prevalences of the condition, while the prevalences reported in Eastern and Central Europe and Asia is lower . AD often starts in early infancy; approximately 45% of all cases begin within the first 6 months of life, 60% during the first year, and 85% before 5 years of age. Up to 70% of these children outgrow the disorder before adolescence . The prevalence of AD continues to increase, particularly in young children from low-income countries, such as in Africa and East Asia, where there is also often an urban–rural gradient of disease.
There is a wide variety of treatment strategies that has been established for AD. For most of the patients a combination of emollient and anti-inflammatory therapy is regarded as an optimal choice [21,22] (Table 1). A step-wise approach to AD treatment with regard to the disease severity is presented at Figure 1.
- Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC (2005 )The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 22: 192-199. Link: https://goo.gl/yOI8aE
- Kemp AS (2003) Cost of illness of atopic dermatitis in children: a societal perspective. Pharmacoeconomics 21: 105-113. Link: https://goo.gl/wEqE6P
- Mancini AJ, Kaulback K, Chamlin SL (2008) The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol 25: 1-6. Link: https://goo.gl/sKBTMu
- Verboom P, Hakkaart-Van L, Sturkenboom M, De Zeeuw R, Menke H, et al. (2002) The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 147: 716-724. Link: https://goo.gl/SYT7Uh
- Flohr C (2011) Recent perspectives on the global epidemiology of childhood eczema. Allergol Immunopathol (Madr) 39: 174-182. Link: https://goo.gl/3XTeZr
- Arnold RJ, Donnelly A, Altieri L, Wong KS, Sung J (2007) Assessment of outcomes and parental effect on Quality-of-Life endpoints in the management of atopic dermatitis. Manag Care Interface 20: 18-23. Link: https://goo.gl/MPoaxi
- Lewis-Jones S (2006) Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 60: 984-92. Link: https://goo.gl/tcbCDk
- Meltzer LJ, Moore M (2008) Sleep disruptions in parents of children and adolescents with chronic illnesses: prevalence, causes, and consequences. J Pediatr Psychol 33: 279-91. Link: https://goo.gl/anNSTo
- Weisshaar E, Diepgen TL, Bruckner T, Fartasch M, Kupfer J, et al. (2008) Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children. Acta Derm Venereol 88: 234-239. Link: https://goo.gl/PT7TiM
- Wuthrich B (1999) Clinical aspects, epidemiology, and prognosis of atopic dermatitis. Ann Allergy Asthma Immunol 83: 464-470. Link: https://goo.gl/d0lhdU
- Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, et al. (2013) Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy 68: 498-506. Link: https://goo.gl/4RvTRi
- Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, et al. (2001) A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 200156: 813-24. Link: https://goo.gl/j9rHrv
- Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, et al. (2004) Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 113: 832-836. Link: https://goo.gl/Ym31DC
- Zuberbier T, Orlow SJ, Paller AS, Taieb A, Allen R, et al. (2006) Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 118: 226-232. Link: https://goo.gl/ZlXsTc
- Herd RM, Tidman MJ, Prescott RJ, Hunter JA (1996) The cost of atopic eczema. Br J Dermatol 135: 20-23. Link: https://goo.gl/6WBbzK
- Lapidus CS, Schwarz DF, Honig PJ (1993) Atopic dermatitis in children: who cares? Who pays? J Am Acad Dermatol 28: 699-703. Link: https://goo.gl/osXPS3
- Schultz Larsen F, Hanifin JM (1992) Secular change in the occurrence of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 176: 7-12. Link: https://goo.gl/1L8xGO
- Wuthrich B, Schmid-Grendelmeier P (2003) The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated ("extrinsic") and the nonallergic ("intrinsic") AEDS. J Investig Allergol Clin Immunol. 13: 1-5. Link: https://goo.gl/Abn107
- Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, et al. (1999) Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 103: 125-38. Link: https://goo.gl/6xA7J1
- Bieber T (2008) Atopic dermatitis. N Engl J Med 358: 1483-1494.
- Wollenberg A, Schnopp C (2010) Evolution of conventional therapy in atopic dermatitis. Immunol Allergy Clin North Am 30: 351-368. Link: https://goo.gl/mtEgu3
- Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, et al. (2013) Difficult to control atopic dermatitis. World Allergy Organ J 6: 6. Link: https://goo.gl/ntaziw
- Wollenberg A, Bieber T (2009) Proactive therapy of atopic dermatitis--an emerging concept. Allergy 64: 276-278. Link: https://goo.gl/Vum5T3
- Hon KL, Kam WY, Leung TF, Lam MC, Wong KY, et al. (2006) Steroid fears in children with eczema. Acta Paediatr 95: 1451-1455. Link: https://goo.gl/041xRw
- Moret L, Anthoine E, Aubert-Wastiaux H, Le Rhun A, Leux C, et al. (2013) TOPICOP(c): a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS One 8: e76493. Link: https://goo.gl/QZInF6
- Harcharik S, Emer J (2014) Steroid-sparing properties of emollients in dermatology. Skin Therapy Lett 19: 5-10. Link: https://goo.gl/IUBOix
- Siegfried EC, Jaworski JC, Hebert AA (2013) Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol 14: 163-178. Link: https://goo.gl/6pjhPt
- Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, et al. (2016) Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 75: 494-503 e4. Link: https://goo.gl/UoM4WJ
- Zane LT, Chanda S, Jarnagin K, Nelson DB, Spelman L, et al. (2016) Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy 8: 853-866. Link: https://goo.gl/K9vDla
- Draelos ZD, Stein Gold LF, Murrell DF, Hughes MH, Zane LT (2016) Post Hoc Analyses of the Effect of Crisaborole Topical Ointment, 2% on Atopic Dermatitis: Associated Pruritus from Phase 1 and 2 Clinical Studies. J Drugs Dermatol 15: 172-176. Link: https://goo.gl/nxVXVB
- Jarnagin K, Chanda S, Coronado D, Ciaravino V, Zane LT, et al. (2016) Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. J Drugs Dermatol 15: 390-396. Link: https://goo.gl/mUl81J
- Dotterud LK, Wilsgaard T, Vorland LH, Falk ES (2008) The effect of UVB radiation on skin microbiota in patients with atopic dermatitis and healthy controls. Int J Circumpolar Health 6: 254-60. Link: https://goo.gl/r4zW8J
- Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, et al. (2011) A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 128: 353-359. Link: https://goo.gl/evr9eU
- Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke WH, Kaufmann R, et al. (2001) Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 137: 870-873. Link: https://goo.gl/EyXx2X
- Murray ML, Cohen JB (2007) Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 32: 23-27. Link: https://goo.gl/sgiryj
- Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, et al. (2014) Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 71: 327-349. Link: https://goo.gl/g6II0d
- Rijssenbeek-Nouwens LH, Bel EH (2011) High-altitude treatment: a therapeutic option for patients with severe, refractory asthma? Clin Exp Allergy 41: 775-782. Link: https://goo.gl/PZesFd
- Schuh A, Nowak D (2011) [Evidence-based acute and long-lasting effects of climatotherapy in moderate altitudes and on the seaside]. Dtsch Med Wochenschr 136: 135-139. Link: https://goo.gl/50BhTB
- Ring J, Brockow K, Abeck D (1996) The therapeutic concept of "patient management" in atopic eczema. Allergy 51: 206-215. Link: https://goo.gl/TwMhwt
- Gauger A, Mempel M, Schekatz A, Schafer T, Ring J, et al. (2003) Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema. Dermatology 207: 15-21. Link: https://goo.gl/qhFMmq
- Ricci G, Patrizi A, Bellini F, Medri M (2006) Use of textiles in atopic dermatitis: care of atopic dermatitis. Curr Probl Dermatol 33: 127-143. Link: https://goo.gl/h2BiEY
- Boneberger S, Rupec RA, Ruzicka T (2010) Complementary therapy for atopic dermatitis and other allergic skin diseases: facts and controversies. Clin Dermatol 28: 57-61. Link: https://goo.gl/p4khES
- Hon KL, Leung TF, Wong Y, Lam WK, Guan DQ, et al. (2004) A pentaherbs capsule as a treatment option for atopic dermatitis in children: an open-labeled case series. Am J Chin Med 32: 941-950. Link: https://goo.gl/ApfsVG
- Hon KL, Lee VW, Leung TF, Lee KK, Chan AK, et al. (2006) Corticosteroids are not present in a traditional Chinese medicine formulation for atopic dermatitis in children. Ann Acad Med Singapore 35: 759-763. Link: https://goo.gl/5SAJQ7
- Salameh F, Perla D, Solomon M, Gamus D, Barzilai A, et al. (2008) The effectiveness of combined Chinese herbal medicine and acupuncture in the treatment of atopic dermatitis. J Altern Complement Med 14: 1043-1048. Link: https://goo.gl/yC3XqO
- Jonas W, Jacobs J (1996) Healing With Homeopathy. Link: https://goo.gl/7wjrKG
- Itamura R, Hosoya R (2003) Homeopathic treatment of Japanese patients with intractable atopic dermatitis. Homeopathy 92: 108-114. Link: https://goo.gl/9CFi6u
- Frenkel M, Hermoni D (2002) Effects of homeopathic intervention on medication consumption in atopic and allergic disorders. Altern Ther Health Med 8: 76-79. Link: https://goo.gl/7TxPbE
- Grillo M, Gassner L, Marshman G, Dunn S, Hudson P (2006) Pediatric atopic eczema: the impact of an educational intervention. Pediatr Dermatol 23: 428-436. Link: https://goo.gl/KaAAGR